NeurologyCrucible Therapeutics spins out with £5mUniversity of Sheffield spinout gets £5m for gene therapies targeting ALS and FTD, advancing towards clinical trials. more ➔
M&AOxford Biomedica acquires ABL Europe for ...Oxford Biomedica’s proposed acquisition of ABL Europe from Institut Mérieux, at a consideration of €15m propels global leadership in cell and gene therapy. more ➔
Austrian Kern Tec raises €12m in Series...Austrian Kern Tec GmbH has raised €12m in the biggest Series A financing ever seen for a foodtech company in Austria to scale food production from waste. more ➔
partnershipBenevolentAI Ltd inks US$594m partnership...British drug discovery specialist BenevolentAI Ltd has licenced its end-to-end AI platform capabilities to Merck KGaA to deliver novel drug candidates for three targets in oncology, neurology and im … more ➔
FinancingAboleris Pharma bags €27.3m in Series A...Autoimmunity specialist AbolerIS Pharma will use a €27.3m Series A Financing to advance its first-in-class antibody inducing immune tolerance in rheumatoid arthritis into the clinic. more ➔
Novel FoodGerman company aims for the first EU appro...The Cultivated B ist the first company in the world to apply for EU-Novel-Food authorisation of a hotdog made from plant protein and cultivated muscle cells. more ➔
Alzheimer'sResearchers stop brain cell death in Alzhe...A Belgian-British research team has identified the human protein underlying necroptosis of human brain cells in Alzheimer’s mice and stopped cell death. more ➔
M&APierre Fabre Laboratories acquires Vertica...French pharma company Pierre Fabre Laboratories has baged Vertical Bio to push development of the companys NSCLC candidate. more ➔ C more ➔
FinancingBioLamina AB bags €19m funding for expan...French-US-based investment specialist Lauxera Capital Partners announced today that it has invested €17m in Swedish cell culture company BioLamina AB (BioLamina) more ➔
radiopharmaceuticalRadiotherapy R&D partnershipOrano Med SAS and Orbit Discovery Ltd announced a collaboration to develop Peptide Receptor Radionuclide Therapies for cancer cells and develop novel radiopharmaceuticals. more ➔
